FUNDAMENTALS · Fundamentals · US Healthcare

Gyre Therapeutics (GYRE) Fundamentals 2026 — Revenue Analysis | SniperIQ

Gyre Therapeutics (GYRE) is a US-listed Healthcare company in Biotechnology with a market capitalization of $545M, trading at $5.96 on the NASDAQ. This SniperIQ fundamentals page covers Gyre Therapeutics's valuation, profitability (net margin -5.4%), revenue (

17M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$545M
Net Margin-5.4%
Revenue (FY25)
17M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Gyre Therapeutics's market cap?

Gyre Therapeutics (GYRE) has a market capitalization of approximately $545M, trading at $5.96 on the NASDAQ. Market cap moves with the live share price.

What is Gyre Therapeutics's P/E ratio?

Gyre Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Gyre Therapeutics?

Gyre Therapeutics runs a net profit margin of -5.4%, a gross margin of 95.1%, and an operating margin of -0.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Gyre Therapeutics generate?

Gyre Therapeutics reported revenue of

17M for fiscal year 2025, with net income of $5M and earnings per share (EPS) of 0.0563. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Gyre Therapeutics pay a dividend?

Gyre Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Gyre Therapeutics financially healthy?

Gyre Therapeutics carries a debt-to-equity ratio of 0.01x and a current ratio of 4.64x, with a market beta of 4.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Gyre Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gyre Therapeutics (GYRE) the key facts are: market cap $545M, revenue

17M, 52-week range 5.44-9.42. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Gyre Therapeutics's full fundamentals live

Get Gyre Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Odyssey Therapeutics (ODTX) fundamentals · Silence Therapeutics (SLN) fundamentals · Prime Medicine (PRME) fundamentals · 3D Medicines (1244) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons